Treatment of advanced or recurrent adenocarcinoma of the endometrium with doxorubicin and cyclophosphamide

E. Campora; A. Vidali; S. Mammoliti; N. Ragni; P. F. Conte

Treatment of advanced or recurrent adenocarcinoma of the endometrium with doxorubicin and cyclophosphamide

E. Campora, A. Vidali, S. Mammoliti, N. Ragni, P. F. Conte

Research output: Contribution to journal › Article › peer-review

Abstract

Thirteen patients with recurrent or advanced endometrial carcinoma were treated with a combination of doxorubicin (40 mg/m ² IV) and cyclophosphamide (600 mg/m ² IV). All patients had been refractory to prior radiotherapy nd hormone therapy. None of the patients had received prior chemotherapy. Six of the 13 patients (46%) achieved an objective response: 1 complete response (8%) and 5 partial responses (38%). Median overall survival was 10 months (range 3-20 months). Doxorubicin and cyclophosphamide is an active combination in patients with advanced endometrial cancer.

Original language	English
Pages (from-to)	181-183
Number of pages	3
Journal	European Journal of Gynaecological Oncology
Volume	11
Issue number	3
Publication status	Published - 1990

ASJC Scopus subject areas

Obstetrics and Gynaecology
Oncology

Fingerprint Dive into the research topics of 'Treatment of advanced or recurrent adenocarcinoma of the endometrium with doxorubicin and cyclophosphamide'. Together they form a unique fingerprint.

Cite this

@article{14cce22e5fcd4612ac031486e370f531,

title = "Treatment of advanced or recurrent adenocarcinoma of the endometrium with doxorubicin and cyclophosphamide",

abstract = "Thirteen patients with recurrent or advanced endometrial carcinoma were treated with a combination of doxorubicin (40 mg/m 2 IV) and cyclophosphamide (600 mg/m 2 IV). All patients had been refractory to prior radiotherapy nd hormone therapy. None of the patients had received prior chemotherapy. Six of the 13 patients (46%) achieved an objective response: 1 complete response (8%) and 5 partial responses (38%). Median overall survival was 10 months (range 3-20 months). Doxorubicin and cyclophosphamide is an active combination in patients with advanced endometrial cancer.",

author = "E. Campora and A. Vidali and S. Mammoliti and N. Ragni and Conte, {P. F.}",

year = "1990",

language = "English",

volume = "11",

pages = "181--183",

journal = "European Journal of Gynaecological Oncology",

issn = "0392-2936",

publisher = "S.O.G. CANADA Inc.",

number = "3",

}

TY - JOUR

T1 - Treatment of advanced or recurrent adenocarcinoma of the endometrium with doxorubicin and cyclophosphamide

AU - Campora, E.

AU - Vidali, A.

AU - Mammoliti, S.

AU - Ragni, N.

AU - Conte, P. F.

PY - 1990

Y1 - 1990

N2 - Thirteen patients with recurrent or advanced endometrial carcinoma were treated with a combination of doxorubicin (40 mg/m 2 IV) and cyclophosphamide (600 mg/m 2 IV). All patients had been refractory to prior radiotherapy nd hormone therapy. None of the patients had received prior chemotherapy. Six of the 13 patients (46%) achieved an objective response: 1 complete response (8%) and 5 partial responses (38%). Median overall survival was 10 months (range 3-20 months). Doxorubicin and cyclophosphamide is an active combination in patients with advanced endometrial cancer.

AB - Thirteen patients with recurrent or advanced endometrial carcinoma were treated with a combination of doxorubicin (40 mg/m 2 IV) and cyclophosphamide (600 mg/m 2 IV). All patients had been refractory to prior radiotherapy nd hormone therapy. None of the patients had received prior chemotherapy. Six of the 13 patients (46%) achieved an objective response: 1 complete response (8%) and 5 partial responses (38%). Median overall survival was 10 months (range 3-20 months). Doxorubicin and cyclophosphamide is an active combination in patients with advanced endometrial cancer.

UR - http://www.scopus.com/inward/record.url?scp=0025073788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025073788&partnerID=8YFLogxK

M3 - Article

C2 - 2209636

AN - SCOPUS:0025073788

VL - 11

SP - 181

EP - 183

JO - European Journal of Gynaecological Oncology

JF - European Journal of Gynaecological Oncology

SN - 0392-2936

IS - 3

ER -